Granulomatosis with Polyangiitis Market Set for Significant Growth Through 2036 as Targeted, Steroid-Sparing Therapies Reshape the Treatment Landscape

DelveInsight's "Granulomatosis with Polyangiitis Market Insights, Epidemiology, and Market Forecast - 2036" report provides an in-depth understanding of granulomatosis with polyangiitis (GPA), including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, and future market opportunities across the 7MM: the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Download DelveInsight's comprehensive Granulomatosis with Polyangiitis Market Report to explore emerging therapies, key players, and future treatment landscapes: https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Granulomatosis with Polyangiitis Market Report
• The Granulomatosis with Polyangiitis market is anticipated to grow at a significant CAGR during the study period 2022-2036, with the United States expected to maintain its dominant share among the 7MM throughout the forecast period.
• GPA is the most prevalent form of ANCA-associated vasculitis (AAV), with an estimated annual incidence of approximately 10-20 cases per million population worldwide. According to the Vasculitis Foundation, GPA affects roughly 3 per 100,000 people.
• PR3-ANCA-positive disease constitutes the largest serological subgroup of GPA, representing approximately three-quarters of diagnosed cases.
• Market growth is expected to be driven by the increasing use of targeted therapies such as rituximab (RITUXAN) and avacopan (TAVNEOS), along with emerging pipeline agents such as SHR-1703, NS-229, and depemokimab.
• In June 2026, the EMA's CHMP recommended revoking the European Union marketing authorization for TAVNEOS (avacopan) following a review that found the pivotal ADVOCATE trial was conducted in breach of good clinical practice guidelines, rendering the submitted efficacy data unreliable. The review also raised concerns regarding serious safety risks, including fatal drug-induced liver injury.
• Also in June 2026, Amgen presented real-world data at EULAR 2026, showing avacopan continuing to demonstrate efficacy and safety with reduced steroid use in patients with ANCA-associated vasculitis.
• In October 2025, GlaxoSmithKline outlined planned regulatory milestones for depemokimab in EGPA for H2 2026, supporting its potential expansion into eosinophil-driven inflammatory diseases.
• Leading Granulomatosis with Polyangiitis companies developing therapies include GSK, Amgen, NS Pharma, and others.

Access DelveInsight's in-depth Granulomatosis with Polyangiitis Market Analysis for a closer look at promising breakthroughs: https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Granulomatosis with Polyangiitis Market Report Overview
The Granulomatosis with Polyangiitis Market Report provides insights into current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM market size from 2022 to 2036.
The report also covers current treatment practices and algorithms, unmet needs, market opportunities, and key factors influencing the future growth of the GPA treatment landscape.

Granulomatosis with Polyangiitis Overview
Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a rare systemic autoimmune disorder characterized by necrotizing inflammation of small- to medium-sized blood vessels and granuloma formation.
The disease primarily affects the upper respiratory tract, lungs, and kidneys and belongs to the group of ANCA-associated vasculitides. The majority of patients test positive for proteinase 3 (PR3)-ANCA.
GPA can present with a wide range of clinical manifestations, including:
• Chronic sinusitis
• Nasal crusting or ulcers
• Cough
• Hemoptysis
• Pulmonary nodules
• Rapidly progressive glomerulonephritis
• Renal impairment
• Systemic inflammation

If left untreated, GPA can lead to significant and potentially irreversible organ damage.
Diagnosis is based on a combination of clinical presentation, ANCA serology, imaging studies, and histopathological confirmation through tissue biopsy, when feasible.

Granulomatosis with Polyangiitis Emerging Drugs Profile

Depemokimab - GSK
Depemokimab is an ultra-long-acting anti-interleukin-5 (IL-5) monoclonal antibody developed by GlaxoSmithKline for eosinophil-driven inflammatory diseases, including eosinophilic granulomatosis with polyangiitis (EGPA).
By selectively inhibiting IL-5, depemokimab aims to provide sustained suppression of eosinophilic inflammation with less frequent dosing compared with existing IL-5-targeted therapies. The therapy has the potential to reduce disease relapses and corticosteroid dependence.
Depemokimab is currently in Phase III development, with an anticipated US launch in 2030.

NS-229 - NS Pharma
NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor developed by NS Pharma for the treatment of EGPA.
By modulating multiple cytokine signaling pathways involved in eosinophilic inflammation and immune activation, NS-229 aims to reduce vascular inflammation, control disease activity, and decrease corticosteroid dependence.
The therapy is currently in Phase II development.

Explore groundbreaking therapies and clinical trials in the Granulomatosis with Polyangiitis Market: https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Granulomatosis with Polyangiitis Market Report Provides Insights Into
• Detailed assessment of companies developing therapies for GPA, along with market size and market share estimates by therapy.
• Evaluation of therapeutic candidates across Phase III and Phase II stages of development.
• Detailed analysis of collaborations, acquisitions and mergers, licensing agreements, and patent details supporting future market advancement.
• Assessment of marketed and emerging therapies and their potential impact on the GPA treatment landscape.

Granulomatosis with Polyangiitis Companies
Key companies involved in the Granulomatosis with Polyangiitis market include:
• GSK
• Amgen
• NS Pharma
• Others

Granulomatosis with Polyangiitis Market - Route of Administration
The Granulomatosis with Polyangiitis Market Report provides a therapeutic assessment of pipeline and marketed drugs by route of administration.
• Oral
• Subcutaneous
• Intravenous infusion

Granulomatosis with Polyangiitis Market - Molecule Types
Granulomatosis with Polyangiitis products have been categorized under the following molecule types:
• Small Molecule (C5aR Antagonist)
• Monoclonal Antibody
• JAK1 Inhibitor

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments: https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Granulomatosis with Polyangiitis Market Report
• Coverage: 7MM - United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Granulomatosis with Polyangiitis Companies: GSK, Amgen, NS Pharma, and others
• Granulomatosis with Polyangiitis Therapies: Depemokimab, SHR-1703, Avacopan (TAVNEOS), NS-229, Rituximab (RITUXAN), and others
• Granulomatosis with Polyangiitis Market CAGR: Significant growth anticipated during 2026-2036
• Therapeutic Assessment by Clinical Stage: Marketed, Phase III, and Phase II

Find out more in DelveInsight's exclusive Granulomatosis with Polyangiitis Market Report: https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Granulomatosis with Polyangiitis: Overview
4. Epidemiology and Patient Burden Assessment
5. Granulomatosis with Polyangiitis Current Treatment Practices
6. Granulomatosis with Polyangiitis Marketed Drugs
7. Granulomatosis with Polyangiitis Emerging Drugs
8. Granulomatosis with Polyangiitis Pipeline Development Activities
9. Granulomatosis with Polyangiitis Market Outlook and Drug Uptake
10. Granulomatosis with Polyangiitis Market Access and Reimbursement
11. Latest KOL Views on Granulomatosis with Polyangiitis
12. Granulomatosis with Polyangiitis Qualitative Analysis
13. Granulomatosis with Polyangiitis Market Size and Forecast, 2022-2036
14. Granulomatosis with Polyangiitis Key Companies
15. Granulomatosis with Polyangiitis Market Drivers and Barriers
16. Appendix
17. About DelveInsight

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.
Connect with DelveInsight to access high-quality, accurate, and real-time intelligence and stay ahead of the growth curve.

This release was published on openPR.